Research programme: neural regeneration peptides - CuroNZ
Alternative Names: Neuro-regenerative peptides; Neuronal regeneration peptides; NNZ-4921; NRPs programmeLatest Information Update: 28 Sep 2023
At a glance
- Originator Metabolic Pharmaceuticals; Neuren Pharmaceuticals
- Developer CuroNZ
- Class Antidementias; Antiparkinsonians; Antipsychotics; Nerve growth factors; Neuropeptides
- Mechanism of Action Cell differentiation stimulants; CXCR4 receptor modulators; Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis; Parkinson's disease; Schizophrenia
- Discontinued Peripheral nervous system diseases; Retinal disorders; Spinal cord injuries; Stroke
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in New Zealand (Parenteral, Injection)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in New Zealand (Parenteral, Injection)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Schizophrenia in New Zealand (Parenteral, Injection)